

Collaborative Care After Treatment: A Checklist for CAR T-Cell Therapy Centers

This checklist serves as a quick-reference tool for chimeric antigen receptor (CAR) T-cell therapy centers to communicate essential information with referring programs following a patient's treatment. It is intended to complement, but not replace, the treatment summary. Centers may tailor the checklist to include patient-specific guidance for the referring program.

Key Contact Information

Include essential contact details for providers at the center, such as:

- ☐ Primary treating provider
 - Name, cell phone, email
- ☐ CAR T-cell therapy center contact for acute issues
 - 24/7 line, if available
- ☐ Contact for nonurgent updates
 - Email, fax, or secure electronic health record (EHR) portal
- ☐ Social worker/navigator contact.

CAR T-Cell Treatment Course Summary

Include a short summary of treatment course, such as:

- ☐ Date of CAR T-cell infusion
- ☐ Disease response status
 - Complete remission, partial response
- ☐ Summary of prior treatments
 - Chemotherapy, transplant
- ☐ Summary of toxicities experienced
 - Cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, cytopenias
- ☐ Date of last imaging and results
- ☐ List of current post-CAR T-cell medications.

Emergency Considerations and Red Flags

Include guidance to referring program on when to immediately contact the center, such as:

- ☐ Signs of disease relapse
- ☐ Severe or progressive neurologic symptoms
 - Seizures, confusion
- ☐ Recurrent infections or severe immunosuppression
- ☐ Persistent cytopenias without recovery
- ☐ Signs of severe graft-vs-host disease.

Ongoing Toxicity Monitoring and Management

Include summary recommendations for how to monitor and manage ongoing toxicities, such as:

- ☐ Guidance on frequency of complete blood count with differential checks including indications for transfusion and/or growth factor support
- ☐ Indications for bone marrow biopsy (eg, persistent cytopenias)
- ☐ Evaluation for other blood disorders if the patient has frequent/recurrent infections
- ☐ Monitoring of Immunoglobulin G (IgG) levels and when to consider repletion
- ☐ Guidance on when to initiate and/or discontinue prophylactic treatments
- ☐ Evaluation for possible atypical viral or fungal infections if indicated.
 - (eg, persistent fevers).

Screening and Surveillance

Include summary recommendations for screening and surveillance, such as:

- ☐ Frequency of surveillance using CT or PET imaging
- ☐ Frequency of disease-specific blood markers for surveillance
- ☐ Next steps if imaging suggests possible disease relapse
- ☐ Follow IgG levels at each visit and considerations for repletion
- ☐ Continuation of prophylactic treatment and criteria for discontinuation
- ☐ Timing and frequency of vaccinations.

Psychosocial, Practical, and Supportive Care Needs

Include any ongoing practical, social, or emotional support needs of the patient and caregiver that the referring team should be aware of and/or address, such as:

- ☐ Caregiving and/or home health care service needs
- ☐ Referrals for physical or occupational therapy
- ☐ Medical equipment provided by CAR T-cell therapy center for at-home patient monitoring
- ☐ Referral to local mental health provider and/or support group for the patient and caregiver
- ☐ Transportation assistance
- ☐ Recommended nonprofit organizations that offer patient and caregiver support.

Communication Plan Between Referring Program and CAR T-Cell Therapy Center

Include guidance to referring program on updates to provide to the center, such as:

- ☐ Criteria for determining whether an update is urgent or nonurgent in the absence of a shared EHR, and the appropriate communication method
- ☐ When and how to contact CAR T-cell therapy center team in the event of an acute patient issue
- ☐ Status of ongoing toxicities
- ☐ Any new toxicities that arise
- ☐ Patient and caregiver support needs (practical, social, or emotional) that the referring program cannot address
- ☐ Results of disease response surveillance assessments and recommended timeframe for submission of results.

Find more information in the [ACCC CAR T-Cell Therapy Resource Library](#).

Improve care coordination through the complex stages of CAR T-cell therapy with this comprehensive resource bank of curated, nationally available materials for the multidisciplinary care team.

Explore additional resources on CAR T-cell therapy at acc-cancer.org/CAR-T-Tips.

This resource was created in partnership with:



This resource was supported by:



The Association of Cancer Care Centers (ACCC) provides education and advocacy for the cancer care community. For more information, visit acc-cancer.org.

© 2025. Association of Cancer Care Centers. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means without written permission.